The principal objectives of this grant are to secure funding to support the clinical research activity of the Eastern Cooperative Oncology Group (ECOG) at Vanderbilt University Medical Center, to facilitate patient accrual to ECOG trials, and to expand the scientific and administrative contributions made to ECOG by Vanderbilt investigators.
The specific aims of the proposal are: 1) to increase participation in ECOG sponsored clinical trials, 2) to further increase the scientific and administrative contributions to ECOG by Vanderbilt investigators, 3) to continue the development of innovative treatment programs for common solid tumors and hematologic malignancies, 4) to provide basic science expertise for correlative laboratory projects attached to ECOG trials and 5) to maintain a high level of data quality and management for which this institution is known. These goals will be achieved through the close interaction of investigators from medical oncology, radiation oncology, pathology and the section of surgical sciences. The interactions between Vanderbilt and other ECOG institutions will be facilitated by the presence of Vanderbilt investigators on ECOG disease oriented and modality committees. The Vanderbilt-lngram Comprehensive Cancer Center has in place all the necessary elements for the successful execution of cooperative group clinical trials including an outstanding data management staff, excellent outpatient and inpatient facilities in which this work will be undertaken and a long history of cooperative group participation.
|Hodi, F Stephen; Lee, Sandra; McDermott, David F et al. (2014) Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. JAMA 312:1744-53|
|Gonsalves, Wilson I; Mahoney, Michelle R; Sargent, Daniel J et al. (2014) Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147. J Natl Cancer Inst 106:|
|Ciombor, Kristen K; Feng, Yang; Benson 3rd, Al Bowen et al. (2014) Phase II trial of bortezomib plus doxorubicin in hepatocellular carcinoma (E6202): a trial of the Eastern Cooperative Oncology Group. Invest New Drugs 32:1017-27|
|Kahl, Brad S; Hong, Fangxin; Williams, Michael E et al. (2014) Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402. J Clin Oncol 32:3096-102|
|Huang, Jocelin; Nair, Suresh G; Mahoney, Michelle R et al. (2014) Comparison of FOLFIRI with or without cetuximab in patients with resected stage III colon cancer; NCCTG (Alliance) intergroup trial N0147. Clin Colorectal Cancer 13:100-9|
|Dahlberg, Suzanne E; Schiller, Joan H; Bonomi, Philip B et al. (2013) Body mass index and its association with clinical outcomes for advanced non-small-cell lung cancer patients enrolled on Eastern Cooperative Oncology Group clinical trials. J Thorac Oncol 8:1121-7|
|Sticca, Robert P; Alberts, Steven R; Mahoney, Michelle R et al. (2013) Current use and surgical efficacy of laparoscopic colectomy in colon cancer. J Am Coll Surg 217:56-62; discussion 62-3|
|Solin, Lawrence J; Gray, Robert; Baehner, Frederick L et al. (2013) A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst 105:701-10|
|Karp, Daniel D; Lee, Sandra J; Keller, Steven M et al. (2013) Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597. J Clin Oncol 31:4179-87|
|Alberts, Steven R; Sargent, Daniel J; Nair, Suresh et al. (2012) Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA 307:1383-93|
Showing the most recent 10 out of 65 publications